Scientific article published about ExpreS2ion’s human candidate HER-2 virus-like particle vaccine, ES2B-C001
24 oktober, 2022
Abstract excerpt: “…ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.”
This publication is a result of the close research collaboration between University of Bologna and ExpreS2ion as announced in February 2021.
The scientific article reference: Ruzzi F, Palladini A, Clemmensen S, Strøbæk A, Buijs N, Domeyer T, Dorosz J, Soroka V, Grzadziela D, Rasmussen CJ, Nielsen IB, Soegaard M, Semprini MS, Scalambra L, Angelicola S, Landuzzi L, Lollini P-L, Thorn M. Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. Biomedicines. 2022; 10(10):2654 - https://doi.org/10.3390/biomedicines10102654. The article can also be found via this link, as well as via the Research Publications page of ExpreS2ion’s website.
Certified AdviserSvensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se
Ämnen i artikeln
Scientific article published about ExpreS2ion’s human candidate HER-2 virus-like particle vaccine, ES2B-C001
24 oktober, 2022
Abstract excerpt: “…ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.”
This publication is a result of the close research collaboration between University of Bologna and ExpreS2ion as announced in February 2021.
The scientific article reference: Ruzzi F, Palladini A, Clemmensen S, Strøbæk A, Buijs N, Domeyer T, Dorosz J, Soroka V, Grzadziela D, Rasmussen CJ, Nielsen IB, Soegaard M, Semprini MS, Scalambra L, Angelicola S, Landuzzi L, Lollini P-L, Thorn M. Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. Biomedicines. 2022; 10(10):2654 - https://doi.org/10.3390/biomedicines10102654. The article can also be found via this link, as well as via the Research Publications page of ExpreS2ion’s website.
Certified AdviserSvensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se
Ämnen i artikeln
Aktier
Aktieanalyser
Aktier
Aktieanalyser
Marknadsöversikt
1 DAG %
Senast
1 mån
